Acneiform Eruption Induced by Vedolizumab – A Case Report
References
- Marzano AV, Borghi A, Cugno M. Adverse drug reactions and organ damage: the skin. Eur J Intern Med. 2016;28:17-24.
- Berger EM, Gottlieb AB. Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol. 2007;7(4):434-44.
- Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3(1):63-8.
- Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardiz-zone S. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis. J Clin Med. 2022;11(9):2302.
- Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3-15.
- Smith MA, Mohammad RA. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases. Ann Pharmacother. 2014;48(12):1629-35.
- Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-65.
- Loftus EV Jr, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11(4):400-11.
- Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839-51.
- Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
- Magdaleno-Tapial J, Ferrer-Guillén B, Valenzuela-Oñate C, Esteve-Martínez A. Acneiform eruption induced by vedolizumab. Dermatol Online J. 2018;24(10): 13030/qt0vg996xr.
- Gilhooley E, Doherty G, Lally A. Vedolizumab-induced acne in inflammatory bowel disease. Int J Dermatol. 2018;57(6):752-3.
- Blankenship K, Burns L, Scharf M. Vedolizumab-induced acne fulminans: an uncommon and severe adverse effect. Cutis. 2022;110(3):E19-20.
- Shankar Raj HR, Kastuar S, Patel J. S4920 acneiform eruption following transition from intravenous to subcutaneous vedolizumab injection in a patient with Crohn’s disease. Am J Gastroenterol. 2025;120(10 Sup pl 2): S1050.
Language: English
Page range: 26 - 31
Submitted on: Apr 23, 2026
Accepted on: May 6, 2026
Published on: Aug 10, 2026
Published by: Serbian Association of Dermatovenereologists (SAD)
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Tanja Mladenović, Anita Mehmedović, Danijela Popović, Slađana Cekić, Emilija Stefanović, Suzana Makragić, Zorana Zlatanović, Andrija Jović, published by Serbian Association of Dermatovenereologists (SAD)
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.